In the DRC, the treatment of NTDs over the past 17 years has been supported by DNDi in a broad partnership with the government and other donors. We urge governments, public and private funders around the world to continue to support research and development efforts to meet the need for access to treatment for patients.

DNDi's innovative approach and collaborative spirit have revolutionized the treatment of neglected diseases, bringing hope and health to millions of patients. Thanks to our collaboration, the Mycetoma Research Centre is conducting the first-ever double-blind, randomized clinical trial for an effective mycetoma treatment.

People affected by neglected diseases must have access to treatments. DNDi helps to ensure that new medical products are available and affordable for all.

Over the past 20 years, DNDi has made a significant contribution to manufacturing drugs that are affordable in low- and middle-income countries, empowering governments in their disease elimination programmes.

Treatment for children living with HIV is a humanitarian effort. At Cipla, we are proud to have partnered with DNDi in this important mission.

With the necessary will and commitment, we know hepatitis C can be eliminated. Our local and global partnerships, notably with DNDi, are ensuring we have the medical tools and strategies in place to succeed.

We hope our research partnership with DNDi can confirm earlier positive results of a new treatment combination that could help improve the lives of people with cutaneous leishmaniasis in Latin America.

DNDi’s innovative and collaborative approach to pharmaceutical research and development has made a difference in the lives of so many. We are proud to have been a founding partner of DNDi and to stand by you in the fight for equitable access to life-saving medicines.

Because PKDL is not fatal it has largely been ignored by public health efforts, but our research with DNDi shows that early treatment of PKDL patients will be a critical element of any leishmaniasis public health and elimination strategy.

Partnerships are essential to the success of clinical research advances in the treatment of NTDs. The fexinidazole treatment for sleeping sickness is a perfect example of how collaboration can fuel the discovery of drugs that are effective, easy to use and with few side effects.

DNDi's dynamic approach to finding solutions, with their unique ability to coordinate partners like an orchestra conductor, has resulted in bringing together different stakeholders in hepatitis C and dengue. Their innovative approach and collaborative spirit have not only brought hope to millions worldwide but have also set a new standard for neglected disease treatment.

The Ministry of Health, Malaysia is proud to be a founding partner of DNDi. Our partnership puts patients first. We have shown that together, we can improve the lives of millions.

Fexinidazole is a true game-changer for sleeping sickness. If acoziborole, a single-dose treatment, is shown to be safe and effective, we’re hopeful it would provide national programmes an even better tool to help achieve global elimination goals.

We are deeply grateful and proud to have been a part of the team that brought a new, affordable treatment for hepatitis C to the world. We remain committed to collaborating with DNDi and partners to ensure that innovative, affordable treatments reach all those in need.

The value of pharmaceutical research and development cannot be overstated, especially in sub-Saharan Africa. DNDi is fostering collaboration and investment in R&D that is addressing the pressing need for access to safe, effective, and affordable treatments. Together we are working towards creating a brighter future for our communities.

Our invaluable partnership with DNDi has been a source of immense pride for us. Your dedication and commitment over the past two decades have made a remarkable difference to people living with neglected diseases.